Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Nec-1 Protects against Nonapoptotic Cell Death in Cisplatin-Induced Kidney Injury

Full text
Author(s):
Tristao, Vivian Regina [1] ; Goncalves, Paula Fernanda [1] ; Dalboni, Maria Aparecida [1] ; Batista, Marcelo Costa [1] ; Durao, Jr., Marcelino de Souza [1] ; Martins Monte, Julio Cesar [1]
Total Authors: 6
Affiliation:
[1] Univ Fed Sao Paulo, Dept Med, Sao Paulo - Brazil
Total Affiliations: 1
Document type: Journal article
Source: RENAL FAILURE; v. 34, n. 3, p. 373-377, 2012.
Web of Science Citations: 25
Abstract

Background/aims: Necrostatin-1 (Nec-1) inhibits necroptosis, a nonapoptotic cell death pathway. Acute kidney injury (AKI) is a clinical problem of high incidence and mortality. It involves several mechanisms of cell death. We aim to evaluate the effect of Nec-1 in the toxic kidney injury model by cisplatin. Methods: We analyzed the effect of Nec-1 in AKI by cisplatin in human proximal tubule cells by flow cytometry. Results: Our results show that Nec-1 has no effect on apoptosis in renal tubular epithelial cells (Nec-1 + Cis group 13.4 +/- 1.7% vs. Cis group 14.6 +/- 1.4%) (p > 0.05). But, in conditions in which apoptosis was blocked by benzyloxy-carbonyl-Val-Ala-Asp-fluoromethyl ketone (z-VAD-fmk) the use of Nec-1 completely reversed cell viability (Nec-1 + Cis + z-VAD group 72.9 +/- 6.3% vs. Cis group 35.5 +/- 2.2%) (p < 0.05) suggesting that Nec-1 has effect on nonapoptotic cell death (necroptosis). Conclusion: Our findings suggest that the combined use of apoptosis and necroptosis inhibitors can provide additional cytoprotection in AKI. Furthermore, this is the first study to demonstrate that Nec-1 inhibits tubular kidney cell death and restores cell viability via a nonapoptotic mechanism. (AU)

FAPESP's process: 08/09773-4 - The contribution of necroptosis and apoptosis during acute kidney injury
Grantee:Júlio César Martins Monte
Support type: Regular Research Grants